Chapter 44

Care of the Liver Transplant Recipient

Management of Renal Function

Andres F. Carrion

Andres F. Carrion

University of Miami Miller School of Medicine, Miami, FL, USA

Search for more papers by this author
Paul Martin

Paul Martin

University of Miami Miller School of Medicine, Miami, FL, USA

Search for more papers by this author
First published: 12 March 2021
Citations: 1

Summary

One consequence of improved survival following liver transplant (LT) is an aging cohort of recipients at risk of renal dysfunction due to nephrotoxic immunosuppressive agents. Metabolic complications such as hypertension, diabetes mellitus, hyperlipidemia, and obesity are common and may contribute to renal disease. Serum creatinine as a measure of renal function has important limitations. Renal dysfunction frequently occurs in patients with decompensated cirrhosis and its prognostic significance is reflected by inclusion of serum creatinine in the Model for End-Stage Liver Disease. Acute kidney injury (AKI) occurs postoperatively in 17-95% of LT recipients, with the wide range mainly reflecting the lack of a standardized definition of AKI. Post-transplant diabetes associated with long-term use of calcineurin inhibitors (CNIs) increases the risk of renal dysfunction. Systemic hypertension is evident typically early after initiation of CNI therapy. Delayed introduction of CNIs is an attractive therapeutic strategy for patients with renal dysfuncti.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.